Bronstein, Gewirtz & Grossman, LLC Encourages Merck & Co., Inc. (MRK) Stockholders to Inquire about Securi... ACCESSWIRE
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on MRK
    Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Merck & Co., Inc. (MRK) And Encourages Stockholders to Reach Out
    1:00p ET October 25 '26 ACCESSWIRE

    NEW YORK CITY, NY / ACCESS Newswire / October 25, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Merck & Co., Inc. ("Merck" or "the Company") (NYSE:MRK). Investors who purchased Merck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/merck-co-inc-mrk-investigation.Merck Investigation DetailsOn October 22, 2026, an early release of closely watched clinical trial results for Moderna and Merck's joint experimental cancer vaccine appeared on the medical news website Oncology Central before being taken down shortly afterward. According to the briefly published report, combining the companies' personalized mRNA cancer vaccine with Merck's immunotherapy Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone. Following this news, Merck's stock price dropped as much as $1.44 per share, or approximately 0.96%, during intraday trading on October 22, 2026.What's Next for Merck Investors?If you are aware of any facts relating to this investigation or purchased Merck securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/merck-co-inc-mrk-investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911No Cost to Merck InvestorsWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.Why Bronstein, Gewirtz & Grossman, LLC for Merck Securities Investigation?Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide."Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.Follow us for updates on LinkedIn, X, Facebook, or Instagram.Contact InfoPeretz Bronstein, Esq. or Nathan MillerBronstein, Gewirtz & Grossman, LLC917-590-0911 | info@bgandg.comAttorney advertising.Prior results do not guarantee similar outcomes.SOURCE: Bronstein, Gewirtz & Grossman, LLCView the original press release on ACCESS Newswire

    COMTEX_1001649084/2457/2026-10-25T13:00:21

    Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against...
    1:00p ET October 29 '26 ACCESSWIRE
    Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against...
    1:00p ET October 28 '26 ACCESSWIRE
    Bronstein, Gewirtz & Grossman, LLC Encourages Merck & Co., Inc. (MRK)...
    1:00p ET October 27 '26 ACCESSWIRE
    Entera Appoints Global Research and Development Leader Dr. Juan Camil...
    8:00a ET October 27 '26 GLOBE NEWSWIRE
    Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Al...
    1:00p ET October 26 '26 ACCESSWIRE
    A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The...
    8:53a ET October 26 '26 GLOBE NEWSWIRE
    Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Al...
    1:00p ET October 25 '26 ACCESSWIRE
    Bronstein, Gewirtz & Grossman, LLC Is Investigating Merck & Co., Inc....
    1:00p ET October 23 '26 ACCESSWIRE
    Brain Cancer Research: The Race for Better CNS Cancer Treatments Coul...
    10:40a ET October 21 '26 GLOBE NEWSWIRE
    2026 Takes a Promising Turn in the Fight Against Cancer as Five Advan...
    9:59a ET October 7 '26 GlobeNewswire

    Market data provided by News provided by